行情

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

1.530
+0.010
+0.66%
盘后: 1.500 -0.03 -1.96% 18:49 01/17 EST
开盘
1.520
昨收
1.520
最高
1.530
最低
1.500
成交量
6.79万
成交额
--
52周最高
7.39
52周最低
1.190
市值
1,397.04万
市盈率(TTM)
-0.7146
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ATOS 新闻

  • 英国诺丁汉市开始试验无线充电的出租车
  • TechWeb.3小时前
  • 英财政大臣:脱欧后 英国“不会与欧盟结盟”
  • 中国新闻网.3小时前
  • FBI探员力挺苹果:已经为调查提供足够帮助
  • 新浪科技.3小时前
  • 亚马逊手掌支付进行终端测试 Visa等成合作伙伴
  • 新浪科技.4小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

ATOS 简况

Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).
展开

Webull提供Atossa Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。